PortfoliosLab logoPortfoliosLab logo
KPTI vs. ASST
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

KPTI vs. ASST - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Karyopharm Therapeutics Inc. (KPTI) and Asset Entities Inc. Class B Common Stock (ASST). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, KPTI achieves a 15.49% return, which is significantly higher than ASST's 3.05% return.


KPTI

1D
-6.39%
1M
-1.62%
YTD
15.49%
6M
44.31%
1Y
89.31%
3Y*
-36.47%
5Y*
-43.70%
10Y*
-23.75%

ASST

1D
9.27%
1M
-4.46%
YTD
3.05%
6M
-22.78%
1Y
-86.80%
3Y*
-49.05%
5Y*
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

KPTI vs. ASST - Yearly Performance Comparison


2026 (YTD)202520242023
KPTI
Karyopharm Therapeutics Inc.
15.49%-27.45%-21.82%-74.56%
ASST
Asset Entities Inc. Class B Common Stock
3.05%50.46%-84.65%-82.00%

Correlation

The correlation between KPTI and ASST is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.06

Correlation (All Time)
Calculated using the full available price history since Feb 6, 2023

0.08

Fundamentals

Market Cap

KPTI:

$210.08M

ASST:

$937.39M

EPS

KPTI:

-$13.00

ASST:

-$25.54

PS Ratio

KPTI:

0.84

ASST:

71.66

Total Revenue (TTM)

KPTI:

$151.12M

ASST:

$5.73M

Gross Profit (TTM)

KPTI:

$145.13M

ASST:

-$7.43M

EBITDA (TTM)

KPTI:

-$93.05M

ASST:

-$304.63M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

KPTI vs. ASST — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KPTI
KPTI Risk / Return Rank: 7373
Overall Rank
KPTI Sharpe Ratio Rank: 7272
Sharpe Ratio Rank
KPTI Sortino Ratio Rank: 7676
Sortino Ratio Rank
KPTI Omega Ratio Rank: 7171
Omega Ratio Rank
KPTI Calmar Ratio Rank: 7474
Calmar Ratio Rank
KPTI Martin Ratio Rank: 7575
Martin Ratio Rank

ASST
ASST Risk / Return Rank: 1515
Overall Rank
ASST Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
ASST Sortino Ratio Rank: 1616
Sortino Ratio Rank
ASST Omega Ratio Rank: 1818
Omega Ratio Rank
ASST Calmar Ratio Rank: 66
Calmar Ratio Rank
ASST Martin Ratio Rank: 1818
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KPTI vs. ASST - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Karyopharm Therapeutics Inc. (KPTI) and Asset Entities Inc. Class B Common Stock (ASST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


KPTIASSTDifference
Sharpe ratioReturn per unit of total volatility

+1.48

Sortino ratioReturn per unit of downside risk

+2.71

Omega ratioGain probability vs. loss probability

1.22

0.92

+0.30

Calmar ratioReturn relative to maximum drawdown

1.86

-0.91

+2.76

Martin ratioReturn relative to average drawdown

4.59

-1.12

+5.71

KPTI vs. ASST - Sharpe Ratio Comparison

The current KPTI Sharpe Ratio is 0.95, which is higher than the ASST Sharpe Ratio of -0.53. The chart below compares the historical Sharpe Ratios of KPTI and ASST, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


KPTIASSTDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

0.95

-0.53

+1.48

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.46

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

-0.28

Sharpe Ratio (All Time)

Calculated using the full available price history

-0.27

-0.19

-0.08

Drawdowns

KPTI vs. ASST - Drawdown Comparison

The maximum KPTI drawdown since its inception was -99.50%, roughly equal to the maximum ASST drawdown of -97.98%. Use the drawdown chart below to compare losses from any high point for KPTI and ASST.


Loading charts...

Drawdown Indicators


KPTIASSTDifference

Max Drawdown

Largest peak-to-trough decline

-99.50%

-97.98%

-1.52%

Max Drawdown (1Y)

Largest decline over 1 year

-48.36%

-95.98%

+47.62%

Max Drawdown (3Y)

Largest decline over 3 years

-89.32%

-97.25%

+7.93%

Max Drawdown (5Y)

Largest decline over 5 years

-98.36%

Max Drawdown (10Y)

Largest decline over 10 years

-99.15%

Current Drawdown

Current decline from peak

-98.80%

-95.72%

-3.08%

Average Drawdown

Average peak-to-trough decline

-75.28%

-84.13%

+8.85%

Ulcer Index

Depth and duration of drawdowns from previous peaks

19.53%

77.69%

-58.16%

Volatility

KPTI vs. ASST - Volatility Comparison

The current volatility for Karyopharm Therapeutics Inc. (KPTI) is 24.86%, while Asset Entities Inc. Class B Common Stock (ASST) has a volatility of 26.35%. This indicates that KPTI experiences smaller price fluctuations and is considered to be less risky than ASST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


KPTIASSTDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.86%

26.35%

-1.49%

Volatility (6M)

Calculated over the trailing 6-month period

62.32%

82.30%

-19.98%

Volatility (1Y)

Calculated over the trailing 1-year period

94.32%

164.70%

-70.38%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

94.91%

322.72%

-227.81%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

86.51%

322.72%

-236.21%

Dividends

KPTI vs. ASST - Dividend Comparison

Neither KPTI nor ASST has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

KPTI vs. ASST - Financials Comparison

This section allows you to compare key financial metrics between Karyopharm Therapeutics Inc. and Asset Entities Inc. Class B Common Stock. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00M40.00M60.00M80.00M100.00M120.00M20222023202420252026
35.07M
2.76M
(KPTI) Total Revenue
(ASST) Total Revenue
Values in USD except per share items

Frequently Asked Questions


KPTI and ASST have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ASST has higher volatility (26.35%) compared to KPTI (24.86%). In terms of maximum drawdown, KPTI dropped -99.50% vs ASST's -97.98%.

KPTI currently has the higher Sharpe Ratio (0.95 vs -0.53), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for KPTI and ASST

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer